tirzepatide heart failure fda Does Shrink Your Heart? Evidence and Safety Facts SUMMIT: Tirzepatide Improves Outcomes and

Clinical significance Adrenal insufficiency Congenital adrenal hyperplasia Androgen-secreting tumors Hormones of the adrenal medulla Catecholamine synthesis Catecholamines (norepinephrine, epinephrine, dopamine) can also be synthesized at sites in the human body other than the adrenal medulla, such as specific regions of the CNS

Patients taking tirzepatide with insulin or sulfonylureas should be especially cautious and may need medication dose adjustments when consuming alcohol

The effect of tirzepatide on 24-hour mean systolic BP, diastolic BP, and heart rate (HR) measured during 24-hour ambulatory BP monitoring (ABPM) in individuals living with obesity without T2DM, has been evaluated in the SURMOUNT-1 ABPM sub-study.34 After 36 weeks of treatment, tirzepatide was associated with statistically significant and clinically meaningful reductions in the mean 24-hour systolic BP at all doses and reduced diastolic BP at the 2 lower doses.34 Simultaneously, tirzepatide treatment was associated with a dose-dependent increase in the mean 24-hour HR.34 Fortunately, there is no clear evidence that tirzepatide increases the risk of atrial fibrillation.35 5

Pairing them is hypothesized not proven to give broader coverage than either alone

Please consult your healthcare provider before starting or changing any medication or treatment.